Hemminki, Kari http://orcid.org/0000-0002-2769-3316
Zitricky, Frantisek
Försti, Asta
Kontro, Mika
Gjertsen, Bjorn T. http://orcid.org/0000-0001-9358-9704
Severinsen, Marianne Tang http://orcid.org/0000-0003-0996-1812
Juliusson, Gunnar http://orcid.org/0000-0002-7911-7265
Article History
Received: 25 January 2024
Revised: 5 March 2024
Accepted: 6 March 2024
First Online: 14 March 2024
Ethics approval
: Aggregated data from a publicly accessible database were used posing no ethical issues.
: MK reports personal fees from Astellas Pharma, AbbVie, Bristol-Myers Squibb, Faron, Jazz Pharmaceuticals, Novartis and Pfizer and research funding from AbbVie. BTG reports Stock and Other Ownership Interests: Kinn Therapeutics AS, Alden Cancer Therapy AS, Hà Biotech AS. Consulting or Advisory Role: Abbvie, Astellas Pharma, AstraZeneca AS, BerGenBio, Coegin Pharma, GreinDX, Immedica Pharma, Incyte, Laboratories Delbert, MSD (Norge) AS, Novartis, Otsuka. Speakers’ Bureau Company: Pfizer, Sanofi Genzyme, Oslo Cancer Cluster, Novartis. GJ reports advisory board attendance and lecturing for AbbVie, Astellas, and Servier, and research collaboration with Jazz Pharma and Novartis. The other authors declare no conflict.